University of Pennsylvania
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Pennsylvania sits in the top decile of US sponsors by registered trial count (#15 of 15,742 sponsors by registered trial count).
University of Pennsylvania: 1,423 sponsored US clinical trials, 199 recruiting.
University of Pennsylvania sponsors 1,423 registered US clinical trials on ClinicalTrials.gov, 199 of them currently recruiting, and 982 completed. 130 of these trials are in Phase 3-4 (later-stage) and 339 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Top-decile sponsor footprint
University of Pennsylvania ranks in the top decile of sponsors by registered trial count (#15 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
982 of 1,090 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,423 total, page 4 of 29
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
NCT05306080
Naltrexone in AUD Reward Drinkers
NCT05028062
Promoting Recovery After STroke With Amantadine
NCT05140148
Longitudinal Assessment of Traumatic Microvascular Injury-2
NCT05725993
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
NCT05138575
Insomnia Behavioral Intervention Study
NCT05301543
DISE: Phenotyping Obstruction Patterns
NCT05050383
Matching Perfusion and Metabolic Activity in HFpEF
NCT04913805
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
NCT05108818
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
NCT04897334
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
NCT04731272
Ketone Ester Intervention in Alcohol Use Disorder
NCT04616781
Abatacept for the Treatment of Giant Cell Arteritis
NCT04474847
Localizing Epileptic Networks Using MRI and iEEG
NCT04649008
Longitudinal Study for Relapsing Polychondritis
NCT04919538
Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial
NCT04565119
Resuscitative TEE Collaborative Registry
NCT04972526
Prospective 4D CTA of BAV Competence
NCT04645862
Physiological Effects of ANGPTL3 Variants in Humans
NCT04234724
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
NCT04321200
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
NCT05865054
UPenn Observational Research Repository on Neurodegenerative Disease
NCT04715399
Neuroinflammation Imaging in AD
NCT04274998
Optimizing Tobacco Use Treatment for PLWHA
NCT04176172
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
NCT04263792
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
NCT04275453
Parkinson's Disease and Movement Disorders Clinical Database
NCT04997642
Phenotyping Genetic Risk for Type 2 Diabetes
NCT04024631
International CDKL5 Registry
NCT04486768
Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation
NCT03721822
Study of Immune Responses to Influenza Vaccination
NCT03346772
Plantar Fasciitis Randomized Clinical Control Trial
NCT03231150
HoFH, the International Clinical Collaborators Registry
NCT04815005
A Randomized Multicenter Study for Isolated Skin Vasculitis
NCT02939573
Transformative Research in Diabetic Nephropathy
NCT02986984
VCRC Tissue Repository
NCT02967068
International Registry for Patients With Castleman Disease
NCT02817997
PET Tau - Neurodegenerative Disease Imaging
NCT03143374
Autoimmune Blistering Diseases Study
NCT02753777
Vasculitis Pregnancy Registry
NCT02593565
Evaluation of the PACE/PACENET BHL Clinical Program
NCT02463266
High Resolution Retinal Imaging
NCT01866371
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT01851694
One-Time DNA Study for Vasculitis
NCT01241305
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
NCT02945345
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
NCT00552357
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
NCT00457847
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
NCT01510067
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
NCT00315380
Strengthening Intentions
NCT07222774
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 182 |
| Phase 2 | 157 |
| Phase 3 | 43 |
| Phase 4 | 87 |
Therapeutic Areas
What is open in the University of Pennsylvania pipeline
199 recruiting of 1,423 indexed (14% open); 982 completed (69%).
Phase mix: 130 late (III/IV) vs 339 early (I/II) (early-phase heavy).
Top condition: Obesity (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Pennsylvania: open-pipeline peers nationwide
Peers matched on 1,423 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
University of Pennsylvania sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,423 trials (± recruiting share)
- Johns Hopkins University · 1,448 trials · 17% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- Yale University · 1,492 trials · 17% recruiting
- GlaxoSmithKline · 1,345 trials · 4% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Seattle Institute for Biomedical and Clinical Research · 14% recruiting · 43 trials
- University of Illinois at Urbana-Champaign · 14% recruiting · 129 trials
- Johns Hopkins Bloomberg School of Public Health · 14% recruiting · 187 trials
- Milton S. Hershey Medical Center · 14% recruiting · 396 trials
Related
What to do with this University of Pennsylvania page
1,423 registered trials is a research-attention snapshot, not an endorsement of University of Pennsylvania or any single study.
- 199 of University of Pennsylvania's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Pennsylvania studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Pennsylvania pipeline card: 1,423 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.